Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis?

Authors

  • Jean-Charles Duclos-Vallée,

    1.  Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
    • *

      Both these authors contributed equally to this study.

  • Funda Yilmaz,

    1.  Laboratoire d'Anatomopathologie, Hôpital Paul-Brousse, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
    • *

      Both these authors contributed equally to this study.

  • Catherine Johanet,

    1.  Laboratoire d'Immunologie, Hôpital Saint-Antoine, Paris, France
    Search for more papers by this author
  • Anne-Marie Roque-Afonso,

    1.  Laboratoire de Virologie, Hôpital Paul-Brousse, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
  • Michelle Gigou,

    1.  Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
  • Catherine Trichet,

    1.  Laboratoire d'Hématologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
    Search for more papers by this author
  • Cyrille Féray,

    1.  Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France
    Search for more papers by this author
  • Eric Ballot,

    1.  Laboratoire d'Immunologie, Hôpital Saint-Antoine, Paris, France
    Search for more papers by this author
  • Elisabeth Dussaix,

    1.  Laboratoire de Virologie, Hôpital Paul-Brousse, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
  • Denis Castaing,

    1.  Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
  • Henri Bismuth,

    1.  Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
  • Didier Samuel,

    1.  Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author
  • Catherine Guettier

    1.  Laboratoire d'Anatomopathologie, Hôpital Paul-Brousse, Villejuif, France
    2.  UPRES EA 3541, Faculté de Médecine de Paris-Sud, Université Paris XI, France
    Search for more papers by this author

Jean-Charles Duclos-Vallée, Centre Hépato-Biliaire, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France.
Tel.: 01 45 59 30 42; fax: 01 45 59 38 57;
e-mail: jean-charles.duclos-vallee@pbr.ap-hopparis.fr

Abstract

Abstract:  Cryptogenic cirrhosis (CC) is diagnosed in 5–30% of cirrhotic patients overall and 7% of patients who undergo liver transplantation for cirrhosis. In our series of patients transplanted for CC, pre-transplant clinical and histological data and the post-transplant course were reexamined in an attempt to identify the aetiology. Among the 881 patients transplanted in our centre between 1987 and 2000, 28 patients with a median age of 46 yr (range: 18–69) at transplantation were initially classified as having CC. Two patients were excluded because of intense ischaemic lesions caused by chemoembolization prevented histological analysis of the native liver (n = 1) and because of cryptic HBV infection (n = 1). Among the remaining 26 patients, four groups were individualized: (i) patients with chronic inflammatory liver disease with autoimmune features (n = 14, 54%); (ii) patients with features suggestive of non-alcoholic fatty liver disease (n = 3, 11.5%); (iii); patients with incomplete septal cirrhosis (ISC) and vascular liver disease (n = 3), and (iv) patients with unresolved CC (n = 6, 23%). In the autoimmune liver disease group, the median International Autoimmune Hepatitis score was 12.5 (range: 11–19) after reevaluation and review of the post-transplantation course was helpful to confirm the diagnosis with the occurrence of active graft hepatitis in nine patients, with autoantibodies in five patients. The vascular group was characterized by lesions of obliterative portal venopathy and ISC in all native livers. Diagnosis of NAFLD was based on the clinical background of obesity and/or type 2 diabetes and the presence of steatosis or steatohepatitis in native livers and graft biopsies. A definite aetiological diagnosis can be achieved in the majority of patients initially diagnosed with CC. Autoimmune liver disease emerged as the main aetiology (14 of 26 patients, 54%) and frequently recurred on the grafted liver (nine cases). In all cases a precise diagnosis is obviously of practical interest for better management of post-transplant survey and treatment.

Ancillary